Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Apelin-1212 residuesRPRLSHKGPMPFEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Apelin(25-36), APLN(25-36), preproapelin(65-77)
A single IV dose dropped mean arterial pressure by 26 mmHg in normotensive rats. That number outperformed apelin-13 by more than double and apelin-36 by five times (Tatemoto et al.)[1]. Apelin-12 (RPRLSHKGPMPF, CAS 229961-08-4) is the shortest biologically active fragment of the 77-amino-acid preproapelin precursor. It binds the APJ receptor and triggers NO-dependent vasodilation through the PI3K/Akt/eNOS cascade. The limitation is hard to ignore: a plasma half-life of roughly five minutes. No human has ever been dosed with native apelin-12 in a clinical trial. Cardiovascular researchers study it for RAAS counter-regulation and cardioprotection in animal models.
Twenty-six millimeters of mercury. That was the mean arterial pressure drop when Tatemoto's group injected 10 nmol/kg of apelin-12 intravenously into normotensive rats [1]. Apelin-13 managed 11 mmHg. Apelin-36 barely registered at 5 mmHg. Apelin-12 (sequence RPRLSHKGPMPF, CAS 229961-08-4, MW 1533.8 Da) is the shortest active fragment cleaved from the C-terminal end of preproapelin. It binds APJ (APLNR), an orphan GPCR identified in 1993 and deorphanized in 1998 when apelin was isolated from bovine stomach tissue. The vasodilatory mechanism runs through PI3K/Akt/eNOS phosphorylation on endothelial cells; NOS inhibitors completely abolished the blood pressure response, confirming the pathway is obligately NO-dependent. Nobody is self-administering this peptide. Zero Reddit threads exist across r/peptides, r/nootropics, and r/longevity. No grey-market vendor carries it. Academic suppliers (AnaSpec, Bachem, Sigma-Aldrich) charge $42 to $110 per milligram. The five-minute plasma half-life makes subcutaneous bioavailability a genuine open question. Where apelin-12 matters is cardiovascular research. A 2026 systematic review pooling 26 preclinical studies confirmed cardioprotective effects across ischemia-reperfusion models (Khatami et al.)[2]. Apelin-knockout mice developed markedly worse cardiac fibrosis under angiotensin II challenge (Sato et al. 2019)[3]. Amgen's small-molecule APJ agonist AMG 986 reached Phase 1b in heart failure patients [4] but produced no clinically meaningful benefit. Early-stage research with genuine preclinical promise, but years from any human application.
Apelin-12 locks onto APJ (APLNR), a class A GPCR expressed on vascular endothelial cells, cardiomyocytes, and smooth muscle. The receptor couples through Gi/o and Gq alpha subunits, firing multiple downstream signaling cascades depending on the tissue. The vascular pathway is best characterized. APJ activation triggers PI3K, which phosphorylates Akt, which phosphorylates eNOS at Ser1177. Nitric oxide floods the local environment. NO diffuses into adjacent smooth muscle cells, activates soluble guanylyl cyclase, raises cyclic GMP, and the vessel relaxes. Blood pressure drops. Tatemoto's group confirmed this by showing NOS inhibitors completely blocked the depressor response. Inside cardiomyocytes, APJ fires through different branches. ERK1/2 phosphorylation and p70S6K signaling (via PKC) promote cell survival. Apelin-12 blocks mitochondrial cytochrome c release and shuts down caspase activation during ischemic stress. Cells that would die from oxygen deprivation get a survival signal instead. The RAAS counter-regulation piece ties it together. APJ can physically hetero-dimerize with AT1 receptors. Apelin binding shifts the ACE/ACE2 balance toward ACE2, favoring cardioprotective Ang(1-7) over pathological Ang II. Apelin also suppresses TGF-beta1/Smad2/alpha-SMA fibrosis signaling (Lv et al., 2020), reducing collagen deposition and myofibroblast differentiation. Beta-arrestin-mediated APJ internalization begins within minutes of agonist binding, which is why receptor desensitization becomes relevant with repeated dosing.
Potent APJ receptor agonist with well-characterized vasodilatory and cardioprotective effects in preclinical models; no human dosing data exists for native apelin-12 specifically: all human trials use [Pyr1]apelin-13 or small-molecule APJ agonists
Cardioprotective Effects of Apelin in Myocardial Ischemia/Reperfusion Injury: A Systematic Review and Meta-Analysis (Khatami et al., J Cardiovasc Pharmacol, Feb 2026, PMID 41150851): 26 preclinical studies; apelin-12 not isolable as a distinct subgroup. AMG 986 Phase 1b (Hellawell et al. 2022, PMID 35460392) tested a small-molecule APJ agonist in HFrEF patients: no clinically meaningful benefit observed.
All human apelin research uses [Pyr1]apelin-13 isoform (e.g., Edinburgh CKD crossover trial, Nature Comm 2024, PMID 39402039): not apelin-12. Plasma half-life ~5 minutes makes SC bioavailability uncharacterized and likely inadequate for sustained APJ engagement. No in vivo PK data for SC apelin-12 in any species.
No community use: zero Reddit threads found across r/peptides, r/nootropics, r/longevity, r/PeptideResearch. No grey-market vendor carries apelin-12. No self-administration protocols exist anywhere.
Apelin-12 has zero community use footprint. It exists exclusively in preclinical cardiovascular research. All human APJ agonist work uses [Pyr1]apelin-13 isoform or small molecules: the community has never adopted native apelin-12.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50mcg | Daily |
| Moderate | 150mcg | Daily |
| Aggressive | 300mcg | Daily |
Reconstitution math for a 2 mg vial: add 2 mL bacteriostatic water to get 1 mg/mL (1000 mcg/mL). At that concentration, the beginner dose of 50 mcg is 5 units on a 100-unit insulin syringe. Moderate (150 mcg) is 15 units. Aggressive (300 mcg) is 30 units. With a 5 mg vial and 2 mL bacteriostatic water, you get 2.5 mg/mL (2500 mcg/mL). Beginner dose becomes 2 units. Moderate is 6 units. Aggressive is 12 units. Reconstituted apelin-12 lasts about 7 days at 2 to 8 degrees Celsius. Don't prep more than a week's supply at a time. Lyophilized powder stores well at minus 20 degrees with desiccant. The five-minute half-life is the elephant in the room. Every impressive rat data point used IV bolus dosing. SC absorption kinetics for apelin-12 have never been measured in any species. If you see no BP response after two weeks at moderate dosing, inadequate SC bioavailability is the most likely explanation. You need a blood pressure cuff before you need a syringe. Baseline BP is not optional.
No established human cycling protocols exist. The 4-on/2-off recommendation is precautionary. The extremely short half-life (~5 minutes) means systemic accumulation is unlikely, but receptor desensitization with repeated daily dosing is a theoretical concern. APJ receptor internalization occurs rapidly after agonist binding, and repeated stimulation may downregulate surface receptor expression. Discontinue if any adverse effects such as dizziness, lightheadedness, or symptomatic hypotension occur.
APJ receptor (class A GPCR) undergoes rapid internalization after agonist binding: β-arrestin-mediated endocytosis begins within minutes of APJ activation. Repeated daily agonism risks downregulating surface APJ expression, reducing pharmacodynamic response over time. The 4-week on/2-week off schedule is a precautionary placeholder extrapolated from general GPCR desensitization principles; no empirical cycling data exists for apelin-12.
Or use the universal Peptide Calculator for any peptide.
Expected: Unknown in humans. In rats (IV): 26±5 mmHg MAP reduction at peak. SC exposure may be insufficient for measurable hemodynamic effects given uncharacterized SC bioavailability. No efficacy endpoints are validated for human SC use.
Monitor: Baseline BP required before first dose. Check BP at 15 and 30 min post-injection each day in week 1. Discontinue if diastolic drops below 60 mmHg or symptomatic hypotension occurs.
Gather supplies: lyophilized apelin-12 vial, bacteriostatic water, alcohol swabs, 29-gauge or 30-gauge insulin syringe (100-unit), blood pressure cuff.
Record the reading. If systolic is below 100 or diastolic below 65, skip the dose.
Draw 2 mL bacteriostatic water for a 2 mg vial (yields 1000 mcg/mL). Inject the water slowly along the vial wall. Don't shake. Gentle swirling only.
Beginner: 50 mcg = 5 units. Moderate: 150 mcg = 15 units. Aggressive: 300 mcg = 30 units. All calculations based on 1000 mcg/mL concentration.
Clean the injection site on the lower abdomen with an alcohol swab. Pinch a fold of skin and insert the needle at 45 degrees. Inject slowly. Rotate sites daily.
Take blood pressure at 15 minutes and 30 minutes.
If diastolic drops below 60 mmHg or dizziness occurs, lie flat and elevate your legs until it passes.
Avoid dosing within 2 hours of antihypertensive medications.
If splitting to BID (morning and evening, 12 hours apart), total daily dose should not exceed the aggressive tier of 300 mcg. BID dosing is entirely unvalidated.
Label with the reconstitution date. Use within 7 days.
30–300 nmol/min IV infusion used in human [Pyr1]apelin-13 trials (Japp et al. 2010, PMID 20385929; Edinburgh CKD trial 2024, PMID 39402039). No equivalent IV protocol tested for native apelin-12 in humans. 10 nmol/kg IV bolus used in rat studies.
All published mechanistic pharmacology used IV bolus or slow infusion to characterize peak hemodynamic effects. SC is speculative. IV is not appropriate for self-administration outside a clinical research setting.
Complementary cardioprotective mechanisms: SS-31 targets the mitochondrial inner membrane to reduce ROS during ischemia-reperfusion; apelin-12 provides RAAS counter-regulation and NO-dependent vasodilation/preload reduction. Mechanistic rationale from preclinical cardiac models: no published combination data exists.
Theoretical longevity/metabolic pairing: MOTS-c activates AMPK for metabolic regulation; apelin-12 provides RAAS counter-regulation and cardiovascular signaling. Mentioned in longevity community discussions. Zero combination research exists.
Both are mitochondria-related cytoprotective peptides with cardiovascular relevance. Theoretical cardioprotective pairing in cardiac stress models. No combination data.
HIGHEST PRIORITY INTERACTION: Neprilysin is the only enzyme that fully inactivates apelin peptides: ACE2 cleavage produces a 12-aa metabolite ([Pyr1]apelin-13(1-12)) that retains substantial vasodilatory activity (pKi 8.04, comparable forearm blood flow in humans, PMC5329011). Sacubitril blocks this sole full-inactivation pathway, potentially causing dramatically prolonged and amplified hypotensive and hemodynamic effects.
Do not combineApelin-12 is a potent NO-dependent vasodilator. No pharmacokinetic interaction data exists. Additive hypotension risk with any antihypertensive class is a genuine safety concern: the combination could cause symptomatic or dangerous blood pressure reduction.
Do not combineApelin directly opposes vasopressin action at V2 receptors in renal collecting ducts. Combined use may produce unpredictable fluid balance, sodium levels, and blood pressure effects.
Pricing updated 2026-04-09
No human safety data exists for apelin-12. Every risk assessment below comes from animal pharmacology and from the AMG 986 small-molecule APJ agonist trial (Hellawell et al. 2022)[4]. AMG 986 is a different compound class entirely. The most serious expected effect is hypotension. That's the primary pharmacodynamic action, not a side effect in the traditional sense. Apelin-12 drops blood pressure through NO-mediated vasodilation. In normotensive rats, the magnitude was large: 26 mmHg MAP reduction at 10 nmol/kg IV. Anyone already taking antihypertensive medications, or with baseline low blood pressure, faces additive risk with zero interaction data to guide dose adjustments. Orthostatic hypotension is a specific concern. Standing up within 30 minutes of injection could trigger dizziness, lightheadedness, or syncope. The protocol calls for remaining seated for 30 minutes post-injection during the first week. Fluid balance disruption deserves attention. Apelin directly opposes vasopressin action at V2 receptors in renal collecting ducts. What that means for sodium levels, urine output, and total body water during repeated daily dosing has never been studied. A basic metabolic panel (sodium, potassium, creatinine) at baseline and at the end of each 4-week cycle is the minimum monitoring. Standard subcutaneous injection site reactions (redness, swelling, mild pain) are expected with any injectable peptide. No immunogenicity data exists for repeated exogenous apelin-12 administration in humans. The AMG 986 Phase 1b trial tested its small-molecule APJ agonist in healthy subjects and heart failure patients up to 650 mg/day. The safety profile was acceptable. No clinically significant dose-related findings emerged over 14 days. That provides some reassurance about APJ agonism as a target; it tells you nothing about the safety of a 12-amino-acid peptide with a five-minute half-life. APJ receptor desensitization matters pharmacologically. APJ is a class A GPCR that internalizes rapidly after agonist binding. Repeated daily stimulation may downregulate surface receptor expression, reducing response over time. If any initial hemodynamic effect (warmth, mild vasodilation) fades around days 7 through 14, desensitization is the likely explanation. Contraindications: hypotension or orthostatic hypotension, concurrent antihypertensive medications without physician oversight, pregnancy or breastfeeding (zero reproductive toxicology data), active hemorrhage, severe renal impairment, and known hypersensitivity to apelin peptides. The sacubitril interaction deserves its own callout. Neprilysin is the only enzyme that fully inactivates apelin peptides (PMC5329011). Sacubitril blocks neprilysin. Taking apelin-12 while on Entresto (sacubitril/valsartan) could dramatically prolong and amplify the hypotensive response. Avoid that combination entirely. Stop and consult a physician if blood pressure drops below 90/60 mmHg, if dizziness persists, or if presyncope occurs.
Verify Apelin-12 dosing and safety with a second opinion
Available only from academic/pharma research suppliers (AnaSpec, Bachem, Sigma-Aldrich, Peptide.com): no grey-market presence confirmed. No independent third-party purity testing programs exist for apelin-12 research lots. At $42–110/mg, cost-motivated adulteration or isoform substitution (selling apelin-13 or apelin-17 as apelin-12) is a realistic risk.
| Test | When | Target |
|---|---|---|
| Seated blood pressure (manual or validated digital cuff) | Baseline pre-dose; 15 min and 30 min post-injection for all of week 1; then before each injection thereafter | Systolic >100 mmHg and diastolic >60 mmHg post-injection |
| Orthostatic blood pressure (standing vs. seated) | Baseline and weekly during use | <20 mmHg systolic drop upon standing |
| Basic metabolic panel (BMP): sodium, potassium, creatinine | Baseline and at end of 4-week cycle | Sodium 136–145 mEq/L; creatinine within personal baseline range |
Primary pharmacodynamic effect is NO-mediated vasodilation causing BP reduction: this is the only measurable biomarker of actual drug effect accessible outside a clinical setting
Vasodilation combined with postural change can trigger orthostatic hypotension and syncope; especially relevant in the 15–30 min window post-injection
Apelin opposes vasopressin-mediated water reabsorption at V2 receptors in the renal collecting duct; sodium and fluid balance disruption is theoretically possible with sustained use; creatinine monitors renal function in context of fluid shifts
In animal models, intravenous apelin-12 produces an immediate blood pressure reduction peaking within minutes. The 26 mmHg mean arterial pressure drop in rats occurred rapidly after injection and was transient due to the ~5-minute half-life. Any perceived hemodynamic effect in humans would be expected in this acute window.
No established human timeline exists. In repeated-dose animal studies, daily administration maintained cardioprotective signaling. Theoretical subcutaneous dosing would produce brief daily peaks of APJ activation. Measurable biomarker changes (e.g., NO metabolites, blood pressure trends) might be detectable with daily dosing in this timeframe.
In animal I/R injury models, apelin treatment over 2-4 weeks reduced cardiac fibrosis markers and improved ejection fraction measurements. Anti-fibrotic effects via TGF-beta1/Smad2 pathway suppression were apparent in this timeframe in rodent studies.
Long-term data comes from apelin-knockout rescue experiments and chronic infusion studies in rodents. Sustained APJ activation over weeks to months improved cardiac remodeling outcomes. No long-term human data exists for native apelin-12 peptide. The AMG 986 small-molecule APJ agonist was tested for up to 14 days in humans without safety signals.
Minutes 0 to 30: The entire pharmacodynamic window lives here. IV apelin-12 at 10 nmol/kg produced a peak MAP reduction of 26 mmHg within minutes in rats. The effect fully resolved inside 30 minutes because of the five-minute half-life. Any hemodynamic response you might feel (warmth, mild flushing, lightheadedness from NO-mediated vasodilation) happens and ends in this window. Weeks 1 to 2: Daily dosing in animal models maintained cardioprotective signaling (PI3K/Akt/eNOS and ERK1/2) with repeated injections. For SC dosing in humans, the honest answer is uncertain. SC bioavailability has never been measured. You might detect trends in resting blood pressure if the peptide reaches systemic circulation. Keep logging BP at 15 and 30 minutes post-injection. Weeks 2 to 4: Rodent ischemia-reperfusion and cardiomyopathy models showed reduced fibrosis markers and improved ejection fraction over this timeframe. Most of that data used apelin-13, not apelin-12. Anti-fibrotic effects through TGF-beta1/Smad2 suppression were apparent in rodent tissue. Whether SC apelin-12 achieves enough human systemic exposure to replicate this is genuinely uncertain. Watch for signs of APJ desensitization around days 7 through 14. Weeks 4 and beyond: Long-term data comes from knockout rescue experiments and chronic infusion studies in rodents. Sustained APJ activation over weeks to months improved cardiac remodeling. AMG 986 (the small-molecule APJ agonist) was tested safely for 14 days in HFrEF patients but showed no clinically meaningful pharmacodynamic benefit [4]. No long-term human data exists for native apelin-12. The 4-on/2-off cycling schedule is precautionary, not evidence-based.
IV apelin-12 (10 nmol/kg) produces peak MAP reduction of 26±5 mmHg in normotensive rats within minutes; effect fully resolves within ~30 minutes due to 5-min t½. The entire pharmacodynamic window is contained in this period for each injection.
No reports exist: no community use
Daily dosing in animal models maintained cardioprotective signaling cascades (PI3K/Akt/eNOS, ERK1/2) with repeated dosing. SC bioavailability in humans is unknown: effects may not accumulate meaningfully if the peptide degrades before significant absorption.
No reports exist
Rodent I/R and cardiomyopathy models showed reduced cardiac fibrosis markers and improved ejection fraction over 2–4 weeks of apelin treatment. Note: these studies predominantly used apelin-13 isoforms, not apelin-12 specifically.
No reports exist
Apelin-knockout rescue experiments and chronic infusion models in rodents showed improved cardiac remodeling with sustained multi-week exposure. AMG 986 (small-molecule APJ agonist) was tested safely for 14 days in HFrEF patients but produced no clinically meaningful pharmacodynamic benefit. No long-term human data for native apelin-12.
No reports exist
Source: Native apelin peptides have an extremely short plasma half-life of approximately 5 minutes in circulation. ACE2 is the principal endopeptidase responsible for apelin inactivation, cleaving the C-terminal Pro-Phe bond. Neprilysin (NEP 24.11) also hydrolyzes apelin peptide bonds. Tatemoto et al. (2001) demonstrated the transient hemodynamic response consistent with rapid clearance. Modified apelin analogues with lipidation can extend half-life to ~29 hours in rat plasma.
Loading the interactive decay curve.
Apelin-12 carries research-only regulatory status. No FDA approval exists. No Investigational New Drug application has been filed in any country for native apelin-12 peptide. The compound is available exclusively from academic-grade suppliers (AnaSpec, Bachem, Sigma-Aldrich, Peptide.com) for laboratory research purposes. No compounding pharmacy produces apelin-12. No grey-market peptide vendor carries it. Sourcing is limited to research-grade channels at $42 to $110 per milligram. Apelin-12 is not scheduled under any controlled substance act. WADA has not specifically evaluated apelin-12, though any exogenous peptide used for performance purposes may fall under the S0 non-approved substances category. Athletes should assume it could be prohibited in competition. This content is for educational and research purposes only. It does not constitute medical advice. Consult a licensed physician before considering any experimental peptide compound.
Peptide Schedule Research TeamReviewed Apr 202610 Citations
